CDC Shifts to Individualized COVID-19 Vaccine Guidance, recommends Separate chickenpox Shot for Toddlers
The Centers for Disease Control and Prevention (CDC) is moving toward a more personalized approach to COVID-19 vaccination and has issued updated immunization schedules reflecting these changes.The agency also now recommends that toddlers receive the varicella (chickenpox) vaccine as a standalone immunization, rather than combined with the measles, mumps, and rubella (MMR) vaccine.
The updated schedules, which will be available on CDC.gov by October 7, 2025, adopt recent recommendations from the CDC Advisory Committee on Immunization Practices (ACIP) and were approved last week by Acting director of the CDC and Deputy Secretary of Health and Human Services Jim O’Neill.
“Informed consent is back,” O’Neill stated. “The CDC’s 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent. That changes today.”
The shift signals a departure from previous broad recommendations, particularly regarding COVID-19 boosters. While the initial COVID-19 primary series, launched through Operation Warp Speed (OWS), reached an estimated 85% of the U.S. adult population, uptake of subsequent seasonal boosters has been substantially lower, with only 23% of adults following the CDC’s moast recent recommendation, according to the agency’s National immunization Survey. This lower adoption rate followed widespread concerns regarding the safety and efficacy of boosters as the virus became endemic.
ACIP’s guidance now emphasizes a risk-benefit assessment tailored to each individual. For those under age 65, the benefit of vaccination is considered most favorable for individuals with increased risk of severe COVID-19, and lowest for those not at increased risk, based on established CDC risk factors. the U.S. Food and Drug Governance has authorized marketing of COVID-19 vaccines for individuals meeting these criteria, as well as those age 65 and older.
This new approach, referred to as shared clinical decision-making, encourages healthcare providers – including physicians, nurses, and pharmacists – to consider individual patient characteristics beyond age, such as underlying health conditions and vaccine-specific factors, when making immunization recommendations. Importantly, coverage for these vaccinations will continue to be available through existing payment mechanisms, including Medicare, Medicaid, the Children’s Health Insurance Programme, and the Vaccines for Children Program, as well as through insurance plans regulated by the Affordable Care Act.
The change regarding the chickenpox vaccine stems from safety data presented to ACIP by the CDC Immunization Safety Office. The data revealed that healthy toddlers aged 12-23 months have a heightened risk of experiencing febrile seizures – a type of seizure frequently enough triggered by fever – seven to 10 days after receiving the combined MMR and varicella vaccine, compared to receiving the varicella vaccine alone.
The CDC’s move reflects a broader trend toward personalized medicine and aims to rebuild trust in public health recommendations by prioritizing open interaction and shared decision-making between patients and their healthcare providers. The agency hopes this approach will lead to greater vaccine confidence and more effective disease prevention strategies.
